Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study.

Michael Launspach Dennis Temel Emily Ohlendorf Felix Zirngibl Bianca Materne Lena Oevermann Hedwig E Deubzer Anton G Henssen Annette Künkele Patrick Hundsdörfer Horst von Bernuth Axel Pruß Angelika Eggert Arend von Stackelberg Peter Lang Johannes H Schulte

Haematologica

Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg.

Published: January 2023

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827155	PMC
http://dx.doi.org/10.3324/haematol.2022.281134	DOI Listing

Publication Analysis

Top Keywords

rituximab therapy

therapy pediatric

pediatric hematopoietic

hematopoietic stem

stem cell

cell transplantation

transplantation prolonged

prolonged b-cell

b-cell impairment

impairment increases

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!